ALGN

Align Technology's stock has been impacted by several events in the past six months. In July 2026, the Q2 2026 earnings report showed record Clear Aligner revenues but a 10.8% drop in Systems and Services revenue due to a shift towards lower-priced scanners and flexible leasing, with management's Q3 revenue guidance and full-year 2026 outlook disappointing expectations. In June 2026, the European Commission opened an antitrust probe into the company concerning its Invisalign and scanner tying practices. New innovations were introduced in July 2026 across its integrated Align Digital Platform to enhance visualization, streamline workflows, and expand treatment capabilities. Also in July 2026, Align Technology announced strategic initiatives for long-term growth and shareholder value, including adding directors and launching a review after a deal with Elliott Management. At the Baird 2026 Global Healthcare Conference in September 2026, management reiterated that U.S. and global orthodontics markets remain under-penetrated, with growth supported by new products, expanded patient financing, and international expansion, alongside guidance for mid-single-digit case growth and margin expansion. In October 2026, Evercore ISI downgraded Align Technology's stock to 'in-line' and cut its price target, citing a weakening consumer backdrop, a sharp deceleration in September demand indicators, and possible 2027 headwinds, contributing to a stock price decline. The company also set its Q3 2026 earnings date for October 28.